Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

Eric Nuermberger; Sandeep Tyagi; Rokeya Tasneen; Kathy N. Williams; Deepak Almeida; Ian Rosenthal; Jacques H. Grosset

doi:10.1128/AAC.00074-08

Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

Eric Nuermberger, Sandeep Tyagi, Rokeya Tasneen, Kathy N. Williams, Deepak Almeida, Ian Rosenthal, Jacques H. Grosset

School of Medicine

Research output: Contribution to journal › Article › peer-review

169 Scopus citations

Abstract

PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more rapidly than the first-line regimen of rifampin, isoniazid, and pyrazinamide. If applicable to humans, regimens containing this combination may radically shorten the treatment of multidrug-resistant tuberculosis.

Original language	English (US)
Pages (from-to)	1522-1524
Number of pages	3
Journal	Antimicrobial agents and chemotherapy
Volume	52
Issue number	4
DOIs	https://doi.org/10.1128/AAC.00074-08
State	Published - Apr 2008

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.00074-08

Cite this

@article{01271afdb7e64aa48745d304e69cd57c,

title = "Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis",

abstract = "PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more rapidly than the first-line regimen of rifampin, isoniazid, and pyrazinamide. If applicable to humans, regimens containing this combination may radically shorten the treatment of multidrug-resistant tuberculosis.",

author = "Eric Nuermberger and Sandeep Tyagi and Rokeya Tasneen and Williams, {Kathy N.} and Deepak Almeida and Ian Rosenthal and Grosset, {Jacques H.}",

year = "2008",

month = apr,

doi = "10.1128/AAC.00074-08",

language = "English (US)",

volume = "52",

pages = "1522--1524",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "4",

}

TY - JOUR

T1 - Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

AU - Nuermberger, Eric

AU - Tyagi, Sandeep

AU - Tasneen, Rokeya

AU - Williams, Kathy N.

AU - Almeida, Deepak

AU - Rosenthal, Ian

AU - Grosset, Jacques H.

PY - 2008/4

Y1 - 2008/4

N2 - PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more rapidly than the first-line regimen of rifampin, isoniazid, and pyrazinamide. If applicable to humans, regimens containing this combination may radically shorten the treatment of multidrug-resistant tuberculosis.

AB - PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more rapidly than the first-line regimen of rifampin, isoniazid, and pyrazinamide. If applicable to humans, regimens containing this combination may radically shorten the treatment of multidrug-resistant tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=42049101775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049101775&partnerID=8YFLogxK

U2 - 10.1128/AAC.00074-08

DO - 10.1128/AAC.00074-08

M3 - Article

C2 - 18285479

AN - SCOPUS:42049101775

SN - 0066-4804

VL - 52

SP - 1522

EP - 1524

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 4

ER -

Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this